Brexucabtagene Autoleucel in R/R Mantle Cell Lymphoma
Experts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Targeting CD19 With CAR T in R/R DL B-Cell Lymphoma: Brian T. Hill, MD, PhD; Mazyar Shadman, MD, MPH
Doctors from University of Washington and Cleveland Clinic discussed targeting CD19 in CAR T-cell therapy for relapsed/refractory DLBCL.
Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL
Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.
Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas
Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.
Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy
Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.
Dr. Hill on the Role of CAR T-Cell Therapy in Relapsed/Refractory DLBCL
Brian T. Hill, MD, PhD, discusses the role of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.